AAV <i>Ildr2</i> KO mice do not develop hepatic steatosis.

<p>(A,B) qPCR expression of <i>Ildr2</i>, isoforms 1 and 4 in livers of 13-week old mice, 10 days after i.v. injection with AAV-TBG-Cre (<i>Ildr2</i>^<i>AAV</i> KO) or AAV-TBG-GFP (<i>Ildr2</i>^<i>fl/fl</i> controls). (C,D) Liver triglyceride and total cholesterol content at 10 days. (E,F) Plasma triglyceride and total cholesterol concentration at 10 days. (G) qPCR expression of <i>Ildr2</i> (isoform 1 unless otherwise noted) in livers of 13-week old mice 2–12 days after i.v. injection with AAV-TBG-Cre (<i>Ildr2</i>^<i>AAV</i> KO). AAV-TBG-GFP was only administered for the 2-day timepoint (<i>Ildr2</i>^<i>fl/fl</i> controls). (H) qPCR expression of <i>Ildr2</i> in livers of 18-week old mice, 6 weeks after AAV injection (I,J) Liver triglyceride and total cholesterol measurements. (K,L) Plasma triglyceride and total cholesterol concentration at 20, 31 and 42 days after AAV injection. Blood was collected after a 4hr fast. n = 4–5 mice per group. * p<0.05, ** p<0.01, *** p<0.001 for <i>Ildr2</i>^<i>AAV</i> KO vs. <i>Ildr2</i>^<i>fl/fl</i> control.